NCOA3, a new player in melanoma susceptibility and a therapeutic target

Cancer Gene Ther. 2022 May;29(5):399-401. doi: 10.1038/s41417-022-00449-2. Epub 2022 Mar 23.

Authors

Vladimir Bezrookove¹, Mohammed Kashani-Sabet²

Affiliations

¹ Center for Melanoma Research and Treatment, California Pacific Medical Center (CPMC) and Research Institute, San Francisco, CA, USA.
² Center for Melanoma Research and Treatment, California Pacific Medical Center (CPMC) and Research Institute, San Francisco, CA, USA. [email protected].

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

Humans
Melanoma* / genetics
Melanoma* / therapy
Nuclear Receptor Coactivator 3

Substances

NCOA3 protein, human
Nuclear Receptor Coactivator 3

Grants and funding